The DOI matches its Crossref record; 158 of the 158 references it cites were found in a registry or an index.
The role of cytokines in the regulation of NK cells in the tumor environment
Abstract
Natural killer (NK) cells are innate lymphoid cells that are important effectors in the first line of defense toward transformed cells. This is mediated both by direct cytotoxic mechanisms and by production of immunoregulatory cytokines. Recent evidence has shown that NK cells also display memory, similar to the cells of the adaptive immune system. Cytokines are pivotal for the maturation, activation and survival of NK cells. Interleukins (IL)-2, IL-12, IL-15, IL-18, IL-21 and type I interferons positively regulate NK cell function, either independently or in cooperation, whereas other cytokines, such as IL-23 and IL-27, may enhance or suppress NK cell function depending on the context. In the tumor microenvironment, TGFβ, IL-10 and IL-6 suppress NK cell activity not only directly, but also indirectly, by affecting immunosuppressive cells and by antagonizing the effect of stimulatory cytokines, thereby dampening the antitumor response of NK cells and promoting subsequent tumor evasion and progression. Increased understanding of the NK cell response to cytokines has provided a better understanding of their impaired function in tumors which may aid in the development of novel immunotherapeutic strategies to enhance NK cell responses in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Interferon-γ: an overview of signals, mechanisms and functions
Schroder, K., Hertzog, P. J., Ravasi, T., & Hume, D. A. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603252 · Cited by 4,120
Mechanisms of type-I- and type-II-interferon-mediated signalling
Platanias, L. C. (2005) · Nature Reviews Immunology · doi:10.1038/nri1604 · Cited by 3,491
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
The biology of human natural killer-cell subsets
Cooper, M. A., Fehniger, T. A., & Caligiuri, M. A. (2001) · Trends in Immunology · doi:10.1016/s1471-4906(01)02060-9 · Cited by 2,975
Cloning of a new cytokine that induces IFN-γ production by T cells
Okamura, H., Tsutsui, H., Komatsu, T., Yutsudo, M., Hakura, A., Tanimoto, T., Torigoe, K., Okura, T., Nukada, Y., Hattori, K., et al. (1995) · Nature · doi:10.1038/378088a0 · Cited by 2,600
Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
Morgan, D. A., Ruscetti, F. W., & Gallo, R. (1976) · Science · doi:10.1126/science.181845 · Cited by 2,493
Caligiuri, M. A. (2008) · Blood · doi:10.1182/blood-2007-09-077438 · Cited by 1,905
Kiessling, R., Klein, E., & Wigzell, H. (1975) · European Journal of Immunology · doi:10.1002/eji.1830050208 · Cited by 1,824
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736
The role of interleukin-2 during homeostasis and activation of the immune system
Boyman, O., & Sprent, J. (2012) · Nature Reviews Immunology · doi:10.1038/nri3156 · Cited by 1,657
Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 Receptor
Grabstein, K. H., Eisenman, J., Shanebeck, K., Rauch, C., Srinivasan, S., Fung, V., Beers, C., Richardson, J., Schoenborn, M. A., Ahdieh, M., et al. (1994) · Science · doi:10.1126/science.8178155 · Cited by 1,422
IL-12 family cytokines: immunological playmakers
Vignali, D. A. A., & Kuchroo, V. K. (2012) · Nature Immunology · doi:10.1038/ni.2366 · Cited by 1,297
Parham, C., Chirica, M., Timans, J., Vaisberg, E., Travis, M., Cheung, J., Pflanz, S., Zhang, R., Singh, K. P., Vega, F., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5699 · Cited by 1,296
Human NK Cell Education by Inhibitory Receptors for MHC Class I
Anfossi, N., André, P., Guia, S., Falk, C. S., Roetynck, S., Stewart, C. A., Breso, V., Frassati, C., Reviron, D., Middleton, D., et al. (2006) · Immunity · doi:10.1016/j.immuni.2006.06.013 · Cited by 1,211
Lanier, L. L., Le, A. M., Civin, C. I., Loken, M. R., & Phillips, J. H. (1986) · The Journal of Immunology · doi:10.4049/jimmunol.136.12.4480 · Cited by 1,129
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Acute phase reaction and acute phase proteins
Gruys, E., Toussaint, M. J. M., Niewold, T. A., & Koopmans, S. J. (2005) · Journal of Zhejiang University-SCIENCE B · doi:10.1631/jzus.2005.b1045 · Cited by 1,080
Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Liao, W., Lin, J.-X., & Leonard, W. J. (2013) · Immunity · doi:10.1016/j.immuni.2013.01.004 · Cited by 1,075
Rose-John, S. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4989 · Cited by 1,040
CXCR3 ligands: redundant, collaborative and antagonistic functions
Groom, J. R., & Luster, A. D. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.158 · Cited by 1,001
Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospísil, M., Young, H. A., Wolf, S. F., Young, D., Clark, S. C., & Trinchieri, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.869 · Cited by 961
Romee, R., Rosario, M., Berrien-Elliott, M. M., Wagner, J. A., Jewell, B. A., Schappe, T., Leong, J. W., Abdel-Latif, S., Schneider, S. E., Willey, S., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf2341 · Cited by 942
Interleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
Del Prete, G., De Carli, M., Almerigogna, F., Giudizi, M. G., Biagiotti, R., & Romagnani, S. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.2.353 · Cited by 927
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells
Dubois, S., Mariner, J., Waldmann, T. A., & Tagaya, Y. (2002) · Immunity · doi:10.1016/s1074-7613(02)00429-6 · Cited by 913
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
Dendritic Cells Prime Natural Killer Cells by trans-Presenting Interleukin 15
Lucas, M., Schachterle, W., Oberle, K., Aichele, P., & Diefenbach, A. (2007) · Immunity · doi:10.1016/j.immuni.2007.03.006 · Cited by 887
Herberman, R. B., Nunn, M. E., Holden, H. T., & Lavrin, D. H. (1975) · International Journal of Cancer · doi:10.1002/ijc.2910160205 · Cited by 885
Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity
Malek, T. R., & Castro, I. (2010) · Immunity · doi:10.1016/j.immuni.2010.08.004 · Cited by 851
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Rosenberg, S. A., Mulé, J. J., Spiess, P. J., Reichert, C. M., & Schwarz, S. L. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1169 · Cited by 745
The two faces of IL-6 in the tumor microenvironment
Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693
Fehniger, T. A., Shah, M. H., Turner, M. J., VanDeusen, J. B., Whitman, S. P., Cooper, M. A., Suzuki, K., Wechser, M., Goodsaid, F., & Caligiuri, M. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.8.4511 · Cited by 652
Natural-killer cells and dendritic cells: “l'union fait la force”
Walzer, T., Dalod, M., Robbins, S. H., Zitvogel, L., & Vivier, E. (2005) · Blood · doi:10.1182/blood-2005-03-1154 · Cited by 634
Marçais, A., Cherfils-Vicini, J., Viant, C., Degouve, S., Viel, S., Fenis, A., Rabilloud, J., Mayol, K., Tavares, A., Bienvenu, J., et al. (2014) · Nature Immunology · doi:10.1038/ni.2936 · Cited by 614
Targeting the TGFβ pathway for cancer therapy
Neuzillet, C., Tijeras-Raballand, A., Cohen, R., Cros, J., Faivre, S., Raymond, E., & de Gramont, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.001 · Cited by 611
The Two Faces of Interferon-γ in Cancer
Zaidi, M. R., & Merlino, G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0482 · Cited by 593
New insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122308 · Cited by 529
Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek, W., Zagożdżon, R., & Jakobisiak, M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1523-1 · Cited by 495
Romagnani, C., Juelke, K., Falco, M., Morandi, B., D’Agostino, A., Costa, R., Ratto, G., Forte, G., Carrega, P., Lui, G., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.8.4947 · Cited by 494
CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells
Jacobs, R., Hintzen, G., Kemper, A., Beul, K., Kempf, S., Behrens, G., Sykora, K.-W., & Schmidt, R. E. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(2001010)31:10<3121::aid-immu3121>3.0.co;2-4 · Cited by 475
The paradoxical role of IL-10 in immunity and cancer
Mannino, M. H., Zhu, Z., Xiao, H., Bai, Q., Wakefield, M. R., & Fang, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.009 · Cited by 473
Immune Responses in Interleukin-2-Deficient Mice
Kündig, T. M., Schorle, H., Bachmann, M. F., Hengartner, H., Zinkernagel, R. M., & Horak, I. (1993) · Science · doi:10.1126/science.8235625 · Cited by 462
The composition and signaling of the IL-35 receptor are unconventional
Collison, L. W., Delgoffe, G. M., Guy, C. S., Vignali, K. M., Chaturvedi, V., Fairweather, D., Satoskar, A. R., Garcia, K. C., Hunter, C. A., Drake, C. G., et al. (2012) · Nature Immunology · doi:10.1038/ni.2227 · Cited by 450
Evidence for discrete stages of human natural killer cell differentiation in vivo
Freud, A. G., Yokohama, A., Becknell, B., Lee, M. T., Mao, H. C., Ferketich, A. K., & Caligiuri, M. A. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20052507 · Cited by 443
Melero, I., Rouzaut, A., Motz, G. T., & Coukos, G. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0985 · Cited by 435
Caligiuri, M. A., Zmuidzinas, A., Manley, T. J., Levine, H., Smith, K. A., & Ritz, J. (1990) · The Journal of experimental medicine · doi:10.1084/jem.171.5.1509 · Cited by 435
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
Ni, J., Miller, M., Stojanovic, A., Garbi, N., & Cerwenka, A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120944 · Cited by 419
Natural killer cell biology: An update and future directions
Campbell, K. S., & Hasegawa, J. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.07.006 · Cited by 416
Effect of tumor cells and tumor microenvironment on NK‐cell function
Vitale, M., Cantoni, C., Pietra, G., Mingari, M. C., & Moretta, L. (2014) · European Journal of Immunology · doi:10.1002/eji.201344272 · Cited by 412
Romee, R., Cooley, S., Berrien-Elliott, M. M., Westervelt, P., Verneris, M. R., Wagner, J. E., Weisdorf, D. J., Blazar, B. R., Ustun, C., DeFor, T. E., et al. (2018) · Blood · doi:10.1182/blood-2017-12-823757 · Cited by 409
Versatile functions for IL-6 in metabolism and cancer
Mauer, J., Denson, J. L., & Brüning, J. C. (2015) · Trends in Immunology · doi:10.1016/j.it.2014.12.008 · Cited by 407
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., & Konishi, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0224 · Cited by 395
IL-21 in Synergy with IL-15 or IL-18 Enhances IFN-γ Production in Human NK and T Cells
Strengell, M., Matikainen, S., Sirén, J., Lehtonen, A., Foster, D., Julkunen, I., & Sareneva, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.11.5464 · Cited by 394
Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15.
Johnston, J. A., Bacon, C. M., Finbloom, D. S., Rees, R. C., Kaplan, D., Shibuya, K., Ortaldo, J. R., Gupta, S., Chen, Y. Q., & Giri, J. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8705 · Cited by 390
Beyond TGFβ: roles of other TGFβ superfamily members in cancer
Wakefield, L. M., & Hill, C. S. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3500 · Cited by 374
Cutting Edge: Priming of NK Cells by IL-18
Chaix, J., Tessmer, M. S., Hoebe, K., Fuséri, N., Ryffel, B., Dalod, M., Alexopoulou, L., Beutler, B., Brossay, L., Vivier, E., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.3.1627 · Cited by 374
Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo
Stoklasek, T. A., Schluns, K. S., & Lefrançois, L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6072 · Cited by 366
IL-12 synergizes with IL-18 or IL-1β for IFN-γ production from human T cells
Tominaga, K., Yoshimoto, T., Torigoe, K., Kurimoto, M., Matsui, K., Hada, T., Okamura, H., & Nakanishi, K. (2000) · International Immunology · doi:10.1093/intimm/12.2.151 · Cited by 333
The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29
Commins, S., Steinke, J. W., & Borish, L. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.02.026 · Cited by 321
Wang, R., Jaw, J. J., Stutzman, N. C., Zou, Z., & Sun, P. D. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0611308 · Cited by 301
Gene modulation and immunoregulatory roles of Interferonγ
Saha, B., Jyothi Prasanna, S., Chandrasekar, B., & Nandi, D. (2010) · Cytokine · doi:10.1016/j.cyto.2009.11.021 · Cited by 300
IL-18–induced CD83+CCR7+NK helper cells
Mailliard, R. B., Alber, S. M., Shen, H., Watkins, S. C., Kirkwood, J. M., Herberman, R. B., & Kalinski, P. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050128 · Cited by 286
Leong, J. W., Chase, J. M., Romee, R., Schneider, S. E., Sullivan, R. P., Cooper, M. A., & Fehniger, T. A. (2014) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.01.006 · Cited by 285
NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures
Carrega, P., Loiacono, F., Di Carlo, E., Scaramuccia, A., Mora, M., Conte, R., Benelli, R., Spaggiari, G. M., Cantoni, C., Campana, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9280 · Cited by 271
Developmental and Functional Control of Natural Killer Cells by Cytokines
Wu, Y., Tian, Z., & Wei, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00930 · Cited by 269
Cifaldi, L., Prencipe, G., Caiello, I., Bracaglia, C., Locatelli, F., De Benedetti, F., & Strippoli, R. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39295 · Cited by 267
Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Larsen, A. K., Ouaret, D., El Ouadrani, K., & Petitprez, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.012 · Cited by 267
Self-citationNakahira, M., Ahn, H.-J., Park, W.-R., Gao, P., Tomura, M., Park, C.-S., Hamaoka, T., Ohta, T., Kurimoto, M., & Fujiwara, H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.3.1146 · Cited by 261
Interleukin‐35: odd one out or part of the family?
Collison, L. W., & Vignali, D. A. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00704.x · Cited by 260
Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses
Parrish-Novak, J., Foster, D. C., Holly, R. D., & Clegg, C. H. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.5.856 · Cited by 256
Safety and immunologic effects of IL-15 administration in nonhuman primates
Berger, C., Berger, M., Hackman, R. C., Gough, M., Elliott, C., Jensen, M. C., & Riddell, S. R. (2009) · Blood · doi:10.1182/blood-2008-12-189266 · Cited by 244
Wang, K. S., Frank, D. A., & Ritz, J. (2000) · Blood · doi:10.1182/blood.v95.10.3183 · Cited by 241
Differences in signaling pathways by IL-1β and IL-18
Lee, J.-K., Kim, S.-H., Lewis, E. C., Azam, T., Reznikov, L. L., & Dinarello, C. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402800101 · Cited by 237
Tumor-related interleukins: old validated targets for new anti-cancer drug development
Setrerrahmane, S., & Xu, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0721-9 · Cited by 237
Nakamura, K., Kassem, S., Cleynen, A., Chrétien, M.-L., Guillerey, C., Putz, E. M., Bald, T., Förster, I., Vuckovic, S., Hill, G. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.007 · Cited by 233
Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors
Margolin, K., Morishima, C., Velcheti, V., Miller, J. S., Lee, S. M., Silk, A. W., Holtan, S. G., Lacroix, A. M., Fling, S. P., Kaiser, J. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0945 · Cited by 208
Schindler, H., Lutz, M. B., Röllinghoff, M., & Bogdan, C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.5.3075 · Cited by 201
Neyer, L. E., Grunig, G., Fort, M., Remington, J. S., Rennick, D., & Hunter, C. A. (1997) · Infection and Immunity · doi:10.1128/iai.65.5.1675-1682.1997 · Cited by 200
Wennerberg, E., Kremer, V., Childs, R., & Lundqvist, A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1629-5 · Cited by 192
TGF-β family signaling in stem cells
Sakaki‐Yumoto, M., Katsuno, Y., & Derynck, R. (2012) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2012.08.008 · Cited by 186
Cytokine regulation of natural killer cell effector functions
Zwirner, N. W., & Domaica, C. I. (2010) · BioFactors · doi:10.1002/biof.107 · Cited by 182
Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP
Fabbi, M., Carbotti, G., & Ferrini, S. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ru0714-360rr · Cited by 177
Natural killer cells: walking three paths down memory lane
Min‐Oo, G., Kamimura, Y., Hendricks, D. W., Nabekura, T., & Lanier, L. L. (2013) · Trends in Immunology · doi:10.1016/j.it.2013.02.005 · Cited by 175
Derré, L., Corvaisier, M., Charreau, B., Moreau, A., Godefroy, E., Moreau-Aubry, A., Jotereau, F., & Gervois, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.5.3100 · Cited by 174
Paolini, R., Bernardini, G., Molfetta, R., & Santoni, A. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.003 · Cited by 171
Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors
Gras Navarro, A., Björklund, A. T., & Chekenya, M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00202 · Cited by 167
Interleukin‐21 activates human natural killer cells and modulates their surface receptor expression
Skak, K., Frederiksen, K. S., & Lundsgaard, D. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02730.x · Cited by 165
Induction of regulatory Tr1 cells and inhibition of TH17 cells by IL-27
Pot, C., Apetoh, L., Awasthi, A., & Kuchroo, V. K. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.08.003 · Cited by 165
Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer
Romee, R., Leong, J. W., & Fehniger, T. A. (2014) · Scientifica · doi:10.1155/2014/205796 · Cited by 164
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis
Teng, M. W. L., Andrews, D. M., McLaughlin, N. M., von Scheidt, B., Ngiow, S. F., Möller, A., Hill, G. R., Iwakura, Y., Oft, M., & Smyth, M. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003251107 · Cited by 161
Neuroblastoma-Derived TGF-β1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells
Castriconi, R., Dondero, A., Bellora, F., Moretta, L., Castellano, A., Locatelli, F., Corrias, M. V., Moretta, A., & Bottino, C. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202693 · Cited by 159
Interleukin-17 acts as double-edged sword in anti-tumor immunity and tumorigenesis
Qian, X., Chen, H., Wu, X., Hu, L., Huang, Q., & Jin, Y. (2016) · Cytokine · doi:10.1016/j.cyto.2015.09.011 · Cited by 158
Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
Bai, J., Gao, Z., Li, X., Dong, L., Han, W., & Nie, J. (2017) · Oncotarget · doi:10.18632/oncotarget.22690 · Cited by 158
Zwirner, N. W., & Ziblat, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00025 · Cited by 156
Interleukin 35: A Key Mediator of Suppression and the Propagation of Infectious Tolerance
Olson, B. M., Sullivan, J. A., & Burlingham, W. J. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00315 · Cited by 151
Swords into plowshares: IL-23 repurposes tumor immune surveillance
Langowski, J. L., Kastelein, R. A., & Oft, M. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.03.006 · Cited by 149
IL-21 Down-Regulates NKG2D/DAP10 Expression on Human NK and CD8+ T Cells1
Burgess, S., Marusina, A., Pathmanathan, I., Borrego, F., & Coligan, J. (2006) · Journal of Immunology · doi:10.4049/jimmunol.176.3.1490 · Cited by 140
Nachbaur, D., Herold, M., Maneschg, A., & Huber, H. P. (1991) · Annals of Hematology · doi:10.1007/bf01714900 · Cited by 135
Cancer-Induced Immunosuppression: IL-18–Elicited Immunoablative NK Cells
Terme, M., Ullrich, E., Aymeric, L., Meinhardt, K., Coudert, J. D., Desbois, M., Ghiringhelli, F., Viaud, S., Ryffel, B., Yagita∥, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3379 · Cited by 135
IL6 Trans-signaling Promotes KRAS-Driven Lung Carcinogenesis
Brooks, G. D., McLeod, L., Alhayyani, S., Miller, A., Russell, P. A., Ferlin, W. G., Rose‐John, S., Ruwanpura, S. M., & Jenkins, B. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2388 · Cited by 132
Fine tuning type I interferon responses
Hertzog, P. J., & Williams, B. R. G. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.04.002 · Cited by 131
Meazza, R., Azzarone, B. G., Orengo, A. M., & Ferrini, S. (2011) · BioMed Research International · doi:10.1155/2011/861920 · Cited by 130
Interleukin 15 as a promising candidate for tumor immunotherapy
Jakóbisiak, M., Gołąb, J., & Lasek, W. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.04.001 · Cited by 128
Nakajima, C., Uekusa, Y., 岩崎, 正., Yamaguchi, N., Mukai, T., Gao, P. H., Tomura, M., Ono, S., Tsujimura, T., Fujiwara, H., et al. (2001) · Cancer Research · Cited by 122
Park, Y. P., Choi, S., Kiesler, P., Gil-Krzewska, A. J., Borrego, F., Weck, J., Krzewski, K., & Coligan, J. E. (2011) · Blood · doi:10.1182/blood-2011-04-346825 · Cited by 121
Behzadi, P., Behzadi, E., & Ranjbar, R. (2016) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.63.2016.1.1 · Cited by 120
Harnessing NK Cell Memory for Cancer Immunotherapy
Fehniger, T. A., & Cooper, M. A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.005 · Cited by 111
Shaping of NK Cell Responses by the Tumor Microenvironment
Stojanovic, A., Correia, M. P., & Cerwenka, A. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0125-8 · Cited by 105
Advantages and clinical applications of natural killer cells in cancer immunotherapy
Ames, E., & Murphy, W. J. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1469-8 · Cited by 100
Park, I. H., Yang, H. N., Lee, K. J., Kim, T.-S., Lee, E. S., Jung, S., Kwon, Y., & Kong, S. (2017) · Oncotarget · doi:10.18632/oncotarget.16281 · Cited by 99
François, S., Usunier, B., Forgue-Lafitte, M. E., L’Homme, B., Benderitter, M., Douay, L., Gorin, N. C., Larsen, A. K., & Chapel, A. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0117 · Cited by 96
Self-citationArmant, M. A., Delespesse, G., & Sarfati, M. (1995) · PubMed · Cited by 88
IL‐27 stimulates human NK‐cell effector functions and primes NK cells for IL‐18 responsiveness
Ziblat, A., Domaica, C. I., Spallanzani, R. G., Iraolagoitia, X. L. R., Rossi, L. E., Avila, D. E., Torres, N. I., Fuertes, M. B., & Zwirner, N. W. (2014) · European Journal of Immunology · doi:10.1002/eji.201444699 · Cited by 87
Investigation of NK cell function and their modulation in different malignancies
Konjević, G. M., Jurišić, V., Jović, V., Vuletić, A. M., Martinović, K. M., Radenković, S., & Spužić, I. (2012) · Immunologic Research · doi:10.1007/s12026-012-8285-7 · Cited by 86
Self-citationWu, H., Li, P., Shao, N., Ma, J., JI, M., Sun, X., Ma, D., & Ji, C. (2012) · Oncology Letters · doi:10.3892/ol.2012.614 · Cited by 80
Defining Early Human NK Cell Developmental Stages in Primary and Secondary Lymphoid Tissues
Eissens, D., Spanholtz, J., van der Meer, A., van Cranenbroek, B., Dolstra, H., Kwekkeboom, J., Preijers, F. W. M. B., & Joosten, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030930 · Cited by 78
TGF-β1 Downregulates the Expression of CX3CR1 by Inducing miR-27a-5p in Primary Human NK Cells
Regis, S., Caliendo, F., Dondero, A., Casu, B., Romano, F., Loiacono, F., Moretta, A., Bottino, C., & Castriconi, R. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00868 · Cited by 77
Trial Watch: Immunotherapy plus radiation therapy for oncological indications
Vacchelli, E., Bloy, N., Aranda, F., Buqué, A., Cremer, I., Demaria, S., Eggermont, A. M. M., Formenti, S. C., Fridman, W. H., Fucikova, J. P., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214790 · Cited by 76
Aquino‐López, A., Senyukov, V., Vlasic, Z., Kleinerman, E. S., & Lee, D. A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00391 · Cited by 75
de Fries, R. U., & Golub, S. H. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.10.3686 · Cited by 74
Fernandez, N. C., Flament, C., Crépineau, F., Angevin, E., Vivier, É., & Zitvogel, L. (2002) · PubMed · Cited by 73
Regulatory Natural Killer Cells: New Players in the IL-10 Anti-Inflammatory Response
Vivier, É., & Ugolini, S. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.12.001 · Cited by 70
The Regulation and Biological Activity of Interleukin 12
Lee, S. M., Suen, Y., Qian, J. X., Knoppel, E., & Cairo, M. S. (1998) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199809050903 · Cited by 69
Wennerberg, E., Pfefferle, A., Ekblad, L., Yoshimoto, Y., Kremer, V., Kaminskyy, V. O., Juhlin, C. C., Höög, A., Bodin, I., Svjatoha, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0291 · Cited by 65
Yu, C., Young, H. A., & Ortaldo, J. R. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.2.245 · Cited by 65
Montaldo, E., Vacca, P., Vitale, C., Moretta, F., Locatelli, F., Mingari, M. C., & Moretta, L. (2016) · Immunology Letters · doi:10.1016/j.imlet.2016.01.007 · Cited by 62
Gooding, R. P., Riches, P., Dadian, G., Moore, J. L., & Gore, M. E. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.354 · Cited by 58
The Smads: transcriptional regulation and mouse models
Datto, M., & Wang, X.-F. (2000) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(99)00027-1 · Cited by 57
Martinović, K. M., Babović, N. L., Džodić, R. R., Jurišić, V., Matković, S., & Konjević, G. M. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0479-z · Cited by 54
Self-citationZiblat, A., Núñez, S. Y., Iraolagoitia, X. L. R., Spallanzani, R. G., Torres, N. I., Sierra, J. M., Secchiari, F., Domaica, C. I., Fuertes, M. B., & Zwirner, N. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01959 · Cited by 52
Räth, T., Billmeier, U., Waldner, M. J., Atreya, R. N., & Neurath, M. F. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1461-5 · Cited by 51
Common gamma chain cytokines in combinatorial immune strategies against cancer
Pulliam, S. R., Uzhachenko, R. V., Adunyah, S. E., & Shanker, A. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.11.007 · Cited by 51
Fujita, K., Ewing, C. M., Isaacs, W. B., & Pavlovich, C. P. (2010) · International Journal of Cancer · doi:10.1002/ijc.25705 · Cited by 50
TGFß, a Potent Regulator of Tumor Microenvironment and Host Immune Response, Implication for Therapy
Yang, H. H. (2010) · Current Molecular Medicine · doi:10.2174/156652410791317039 · Cited by 46
IL‐18 is produced by prostate cancer cells and secreted in response to interferons
Lebel‐Binay, S., Thiounn, N., Pinieux, G. D. B. D., Vieillefond, A., Debré, B., Bonnefoy, J., Fridman, W. H., & Pagès, F. (2003) · International Journal of Cancer · doi:10.1002/ijc.11285 · Cited by 44
Natural killer cell receptors: alterations and therapeutic targeting in malignancies
Konjević, G. M., Vuletić, A. M., & Martinović, K. M. (2015) · Immunologic Research · doi:10.1007/s12026-015-8695-4 · Cited by 40
Self-citationKonjević, G. M., Martinović, K. M., Vuletić, A. M., & Babović, N. L. (2010) · Melanoma Research · doi:10.1097/cmr.0b013e32833e3286 · Cited by 40
Self-citationGu, X., Tian, T., Zhang, B., Liu, Y., Yuan, C., Shao, L., Guo, Y., & Fan, K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2887-8 · Cited by 36
Model-driven experimental analysis of the function of SHP-2 in IL-6-induced Jak/STAT signaling
Dittrich, A., Quaiser, T., Khouri, C., Görtz, D., Mönnigmann, M., & Schaper, F. (2012) · Molecular BioSystems · doi:10.1039/c2mb05488d · Cited by 32
Konjević, G. M., Martinović, K. M., Vuletić, A. M., & Radenković, S. (2010) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2010.06.013 · Cited by 27
Self-citationVuletić, A. M., Jovanić, I., Jurišić, V., Milovanović, Z., Nikolić, S., Spurnić, I., & Konjević, G. M. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-9938-3 · Cited by 27
Self-citationSerum-Soluble IL-2 Receptor and IL-6 Levels in Patients with Melanoma
Boyano, M. D., García-Vázquez, M. D., Gardeazábal, J., de Galdeano, A. G., Zubiaga, I. S., Cañavate, M., Ratón, J. A., Bilbao, I., & Díaz-Pérez, J. L. (2009) · Oncology · doi:10.1159/000227726 · Cited by 23
Interferons and Their Antitumor Properties
Platanias, L. C. (2013) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2013.0019 · Cited by 23
Stabile, H., Nisti, P., Peruzzi, G., Fionda, C., Pagliara, D., Brescia, P. L., Merli, P., Locatelli, F., Santoni, A., & Gismondi, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342024 · Cited by 22
Uptake of CCR7 by KIR2DS4 + NK Cells Is Induced upon Recognition of Certain HLA-C Alleles
Pesce, S., Carlomagno, S., Moretta, A., Sivori, S., & Marcenaro, E. (2015) · Journal of Immunology Research · doi:10.1155/2015/754373 · Cited by 21
Type I IFN‐mediated synergistic activation of mouse and human DC subsets by TLR agonists
Kreutz, M., Bakdash, G., Dölen, Y., Sköld, A. E., Hout-Kuijer, M. A. V., de Vries, I. J. M., & Figdor, C. G. (2015) · European Journal of Immunology · doi:10.1002/eji.201545583 · Cited by 21
Martinović, K. M., Vuletić, A. M., Babović, N. L., Džodić, R. R., Konjević, G. M., & Jurišić, V. (2017) · Cytokine · doi:10.1016/j.cyto.2017.02.024 · Cited by 20
Self-citationCD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma
Konjević, G. M., Jović, V., Vuletić, A. M., Radulovic, S. S., Jelić, S., & Spužić, I. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01873.x · Cited by 17
Self-citationInterleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases
Danese, S., & Gao, B. (2010) · Gut · doi:10.1136/gut.2008.173534 · Cited by 17
Konjević, G. M., Martinović, K. M., Vuletić, A. M., & Babović, N. L. (2012) · PubMed · Cited by 13
Self-citationMartinović, K. M., Babović, N. L., Džodić, R. R., Jurišić, V., Ninković, A. Z., & Konjević, G. M. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000289 · Cited by 13
Self-citationDamle, R. N., Advani, S. H., & Gangal, S. G. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01742314 · Cited by 11
Konjević, G. M., Vuletić, A. M., Martinović, K. M., Krivokuća, A., Jankovic, R. N., & Babović, N. L. (2017) · The Journal of Membrane Biology · doi:10.1007/s00232-017-9977-7 · Cited by 9
Self-citationMolecular mechanisms influencing NK cell development: implications for NK cell malignancies.
Mujaj, S., Spanevello, M. M., Gandhi, M. K., & Nourse, J. P. (2011) · PubMed · Cited by 6
Cited by
Sun, L., Su, Y., Jiao, A., Wang, X., & Zhang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01471-y · Cited by 1,014
NK Cell Metabolism and Tumor Microenvironment
Terrén, I., Orrantia, A., Vitallé, J., Zenarruzabeitia, O., & Borrego, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02278 · Cited by 501
NK Cell-Based Immune Checkpoint Inhibition
Khan, M., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 356
Monalizumab: inhibiting the novel immune checkpoint NKG2A
van Hall, T., André, P., Horowitz, A., Ruan, D. F., Borst, L., Zerbib, R., Narni-Mancinelli, E., van der Burg, S. H., & Vivier, E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0761-3 · Cited by 292
High-dimensional single-cell analysis of human natural killer cell heterogeneity
Rebuffet, L., Melsen, J. E., Escalière, B., Basurto-Lozada, D., Bhandoola, A., Björkström, N. K., Bryceson, Y. T., Castriconi, R., Cichocki, F., Colonna, M., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01883-0 · Cited by 276
Metadata
- Authors
- Konjević, G. M., Vuletić, A. M., Mirjačić Martinović, K. M., Larsen, A. K., & Jurišić, V. B.
- Venue
- Cytokine
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 117
- Pages
- 30-40
- ISSN
- 1043-4666 (ISSN-L)
- OpenAlex
- W2915822971
- Cited by
- 279
- References
- 158
- FWCI
- 8.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.